Extra: The MAHA Movement's War On Red Tape And Junk Food
Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary are leading that effort by addressing many things, including what is in our food, our dietary guidelines, and what medications are made available.
Recently, Dr. Makary joined FOX News Rundown host Dave Anthony to discuss his efforts to help improve America's health. He discussed the importance of removing dyes and other chemicals from our foods, and also why our nation needs to rethink its dietary guidelines that he believes have led to America's obesity problem.
Dr. Makary also discussed the dangers of popular energy drinks and gummies containing opioid-like substances that many people may not realize are harmful.
We often have to cut interviews short during the week, but we thought you might like to hear the full interview.
Today on Fox News Rundown Extra, we will share our entire interview with FDA Commissioner Dr. Marty Makary, allowing you to hear even more of his views on how we can improve the health of Americans and why he says we're paying the price for decades of bad policy.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Lysoway Therapeutics Awarded Grant from The Michael J. Fox Foundation to Advance TRPML1 Agonist to Treat Parkinson's Disease
CAMBRIDGE, Mass., August 06, 2025--(BUSINESS WIRE)--Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF's Parkinson's Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson's disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway's novel, highly brain-penetrant small molecule TRPML1 agonist. The study aims to investigate whether activating TRPML1 by a novel, small molecule modulator, will enhance the lysosomal membrane calcium ion channel to restore lysosomal function and help with clearance of alpha-synuclein, the protein that is linked to the disease. "We are honored to receive this generous grant from The Michael J. Fox Foundation," said Valerie Cullen, PhD, Principal Investigator and SVP of Research and Translation at Lysoway. "TRPML1 is a high value target due to its pivotal role in sensing and responding to cellular stress. By activating this ion channel, we can engage multiple beneficial pathways that restore autophagy/lysosomal homeostasis and bolster cellular resilience. Our lead development candidate is both orally bioavailable and highly brain-penetrant, offering strong potential to modify disease progression in Parkinson's Disease." Yongchang Qiu, PhD, Founder and Chief Executive Officer of Lysoway Therapeutics, added "This funding underscores growing confidence in TRPML1 as a compelling target for Parkinson's disease. It will allow us to accelerate development of our lead TRPML1 agonist and to establish key biomarkers for target engagement, with the goal of initiating first-in-human clinical trials early next year." About Lysoway Therapeutics, in Cambridge, MA, Lysoway Therapeutics is a leader in developing therapeutically viable lysosomal ion channel modulators. The company is advancing a pipeline of small molecule activators targeting these channels to treat neurodegenerative diseases. Learn more at View source version on Contacts Media contact: Info@
CNN
31 minutes ago
- CNN
HHS slashes funding for mRNA vaccine development
US Health and Human Services is 'winding down' its mRNA vaccine development and will instead fund other vaccine platforms through the Biomedical Advanced Research and Development Authority, the agency said Tuesday. HHS Secretary Robert F. Kennedy Jr. said in a statement that BARDA would terminate 22 mRNA vaccine development investments, suggesting the vaccines 'fail to protect effectively against upper respiratory infections like Covid and flu,' despite evidence they protect against severe disease and death from Covid-19 and show promise against influenza. HHS said some final stage contracts will continue, but 'no new mRNA-based projects will be initiated.' 'We reviewed the science, listened to the experts, and acted,' Kennedy said. 'Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices,' HHS said. 'Technologies that were funded during the emergency phase but failed to meet current scientific standards will be phased out in favor of evidence-based, ethically grounded solutions – like whole-virus vaccines and novel platforms.' Messenger RNA is a single strand of the genetic code that cells can 'read' and use to make a protein. With the Covid vaccine, mRNA instructs cells in the body to make the particular piece of the virus's spike protein. When the immune system sees it, it recognizes it as foreign and is then prepared to attack when there is an actual infection. The vaccines were particularly useful during the Covid-19 pandemic because they can be developed and manufactured quickly. Multiple peer-reviewed studies have shown that mRNA vaccines developed under Operation Warp Speed during the first Trump administration were highly effective at preventing severe disease and were repeatedly demonstrated to be extremely safe. The Trump administration and Kennedy, who has a long history of anti-vaccine claims, had previously said they were evaluating mRNA projects. In May, HHS also terminated a $590 million contract with Modern to develop a vaccine to protect against bird flu. Dr. Peter Hotez, a pediatrician who directs the Center for Vaccine Development at Texas Children's Hospital, said Tuesday's HHS announcement will 'promote their pseudoscience agenda and weaken our nation's biosecurity.' 'The mRNA technology, like all biotechnologies, has strengths and weaknesses, but for a pandemic situation with a new and previously unknown pathogen, or for cancer vaccines and immunotherapeutics it has distinct advantages,' Hotez said. 'HHS under Mr. Kennedy is telling us that we should no longer look to the federal government for innovation in biomedicine. The states are on their own.' HHS said it is canceling BARDA's award to Moderna/UTMB for an mRNA vaccine for H5N1, known as avian flu. It is also terminating contracts with Emory University and Tiba Biotech. Emory has been working on a dry powder mRNA antiviral platform that could be inhaled and Tiba is working on a platform that uses a nanoparticle carrier technology, according to the BARDA website. HHS also said it is 'de-scoping' mRNA-related work in contracts it has with Luminary Labs, ModeX, and Sequirus. HHS said it was also rejecting or canceling multiple pre-award solicitations with proposals from Pfizer, Sanofi Pasteur, CSL Sequirus, Gritstone and others. And it was also restructuring collaborations with the US Department of Defense that would impact nucleic acid-based vaccine projects with AAHI, AstraZeneca and HDT Bio. HHS said the impacted projects were worth about $500 million. 'Other uses of mRNA technology within the department are not impacted by this announcement,' it said. In a statement, Moderna spokesman Kelly Cunningham said, 'We are not aware of any new contract cancellations by BARDA involving Moderna. As previously announced in May, our pandemic flu contract was canceled, and we do not currently have any active collaboration with BARDA.' A spokesperson for Gritstone said the company ceased operations 'as a company some time ago.' AstraZeneca declined to comment. CNN reached out to Tiba Biotech, Emory, Pfizer, ModeX, Luminary Labs, CSL Seqirus and Sanofi for a response. Dr. Paul Offit, a vaccine scientist at Children's Hospital of Philadelphia and an outside vaccine adviser to the FDA criticized Kennedy for making 'a policy decision again that contradicts the scientific data.' 'He has said things like the mRNA vaccines are unnecessarily dangerous,' Offit said. 'It's just wrong. I mean it's actually remarkably safe and it's effective.' 'A decision based on cutting back all this funding based on false statements is just hard to watch,' Offit added. If another pandemic comes 'we'll just be behind the eight ball again,' without additional research into mRNA vaccines. 'All it does is put us at unnecessary risk for no good reason and just a few bad reasons too,' Offit said. Dr. Jake Scott, an infectious diseases doctor in California who worked many long days treating patients during the Covid-19 pandemic, said he lost several patients early in the pandemic, but the mRNA vaccines brought major changes by safely protecting billions of people from severe disease and death. 'I cannot really convey accurately what a profound difference there was in the hospital pre vaccine and post vaccine and that was thanks to the mRNA technology,' said Scott, a clinical associate professor, medicine - infectious disease with Stanford Medicine. To hear that HHS was going to eliminate investment in mRNA vaccines, Scott said, is 'really depressing.' 'This just hits differently. It makes me sad. It's kind of heartbreaking,' said Scott.
CBS News
31 minutes ago
- CBS News
Texas bans soda and candy purchases with SNAP benefits beginning April 2026, Gov. Abbott says
Texans participating in a federal program that helps low-income individuals and families buy food will no longer be allowed to purchase sweetened drinks and candy, effective April 1, 2026, Gov. Greg Abbott announced Tuesday. Earlier this year, Abbott submitted a request to the U.S. Department of Agriculture's Food and Nutrition Service, seeking a waiver to prohibit such purchases using SNAP — the Supplemental Nutrition Assistance Program — benefits. SNAP serves about 3.5 million low-income Texans. Those who qualify for SNAP receive a special card — similar to a debit card — to use at grocery stores for fruits, vegetables, meats, cereals, milk, plants, and garden seeds. The goal, according to federal officials, is to ensure everyone can access nutritious food, even during tough financial times. "By restricting unhealthy foods from being purchased with SNAP benefits, Texas can help ensure the health and well-being of Texans," Abbott said in a statement. "The new SNAP guidelines will ensure taxpayer dollars are used to purchase foods that provide real nutritional value." About 80 cents of every dollar in SNAP benefits is used to purchase staples like meat, bread, milk, cereal, and rice. The rest goes to salty snacks, candy, and sweetened beverages, according to the Brookings Institution. According to the waiver, SNAP recipients will no longer be able to buy candy, drinks with artificial sweeteners, and drinks with 5 grams or more of added sugar. Abbott thanked U.S. Secretary of Agriculture Brooke Rollins and the Trump administration for approving the waiver. "Working together, we will build a stronger, healthier Texas," Abbott said. According to the governor's office, the Texas Health and Human Services Commission will be educating retailers on SNAP-eligible foods and enforcement.
